Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v3-EN
Language English English
Date Updated 2019-05-10 2019-05-09
Drug Identification Number 02241819 02241819
Brand name AVALIDE AVALIDE
Common or Proper name Avalide Avalide
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients HYDROCHLOROTHIAZIDE IRBESARTAN HYDROCHLOROTHIAZIDE IRBESARTAN
Strength(s) 12.5MG 300MG 12.5MG 300MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 90 90
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2019-04-17 2019-04-17
Estimated end date 2019-05-17 2019-05-17
Actual end date 2019-05-09 2019-05-09
Shortage status Resolved Actual shortage
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments